Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Grace Hwei Ching TanClaramae Shulyn ChiaSze Huey TanKhee Chee SooMelissa Ching Ching TeoPublished in: International journal of clinical oncology (2018)
There remains a 27% risk of ER after CRS-HIPEC. Better patient selection and the administration of adjuvant chemotherapy may help to reduce ER.